Familiarity breeds opportunity

Confidence in Y-mAbs Therapeutics Inc.’s management team and late-stage programs in pediatric oncology where treatment options are sparse drove HBM Partners' decision to lead the company's $50 million venture round.

Undisclosed existing investors also participated in the financing, announced on Oct. 24. The biotech had previously raised $37 million in two venture rounds since its founding in 2014. ...